Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

TBG Diagnostics stock

TDL.AX
AU000000TDL4
A2AD8F

Price

0.27
Today +/-
+0
Today %
+0 %
P

TBG Diagnostics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the TBG Diagnostics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the TBG Diagnostics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the TBG Diagnostics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze TBG Diagnostics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

TBG Diagnostics Stock Price History

DateTBG Diagnostics Price
4/12/20210.27 undefined
4/9/20210.27 undefined

TBG Diagnostics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into TBG Diagnostics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by TBG Diagnostics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects TBG Diagnostics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of TBG Diagnostics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into TBG Diagnostics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing TBG Diagnostics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on TBG Diagnostics’s growth potential.

TBG Diagnostics Revenue, EBIT and net profit per share

DateTBG Diagnostics RevenueTBG Diagnostics EBITTBG Diagnostics Net Income
2025e213 M undefined0 undefined0 undefined
2024e182.76 M undefined0 undefined0 undefined
2023e156.76 M undefined0 undefined0 undefined
2022e128.99 M undefined0 undefined0 undefined
2021e112.7 M undefined0 undefined0 undefined
20204.63 M undefined-3.04 M undefined-3.55 M undefined
20193.44 M undefined-2.05 M undefined764,940 undefined
20183.24 M undefined-2.64 M undefined-4.15 M undefined
20174.6 M undefined-1.71 M undefined-6.54 M undefined
20161.39 M undefined-2.81 M undefined-2.62 M undefined
2015806,590 undefined-1.86 M undefined-1.86 M undefined
20145.75 M undefined-1.81 M undefined-1.81 M undefined
20133.51 M undefined-2.81 M undefined-2.09 M undefined
20122.89 M undefined-3.44 M undefined-3.44 M undefined
20113.67 M undefined-6.05 M undefined-6.1 M undefined
20102.71 M undefined-11.4 M undefined-15.84 M undefined
20094.94 M undefined-12.29 M undefined-5.47 M undefined
20086.48 M undefined-25.88 M undefined-26.15 M undefined
20073.78 M undefined-20.66 M undefined-22.45 M undefined
20062.82 M undefined-6.96 M undefined-7.61 M undefined
20053.11 M undefined-5.92 M undefined-5.94 M undefined
20046.19 M undefined-4.46 M undefined-4.78 M undefined
20038.16 M undefined-3.75 M undefined-7.58 M undefined
20025.66 M undefined-4.86 M undefined-6.16 M undefined
20013.55 M undefined-6.32 M undefined-1.15 M undefined

TBG Diagnostics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021e2022e2023e2024e2025e
111435863236423235014334112128156182212
---300.00-25.0066.6760.00-25.00-50.00-33.3350.00100.00-33.33-50.0050.00-33.3350.0066.67--300.00-25.00-33.332,700.0014.2921.8816.6716.48
-100.00-200.00-100.00-25.0066.6760.0075.0066.6766.67-33.3350.0075.00-33.33--60.00--75.0066.6766.6750.00-----
-1-2-1-12364201330100300322200000
-3-5-7-6-6-4-3-4-5-6-20-25-12-11-6-3-2-1-1-2-1-2-2-300000
-300.00-500.00-700.00-150.00-200.00-80.00-37.50-66.67-166.67-300.00-666.67-416.67-300.00-550.00-200.00-150.00-66.67-20.00--200.00-25.00-66.67-66.67-75.00-----
-3-5-7-7-1-6-7-4-5-7-22-26-5-15-6-3-2-1-1-2-6-40-300000
-66.6740.00--85.71500.0016.67-42.8625.0040.00214.2918.18-80.77200.00-60.00-50.00-33.33-50.00-100.00200.00-33.33-------
15.4316.2121.924.6629.2630.4927.136.3139.6845.0749.5366.7660.2827.3427.3427.3427.955.29182.83217.59217.59217.59217.59217.5900000
-----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The TBG Diagnostics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the TBG Diagnostics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020
                                               
3.41.34.610.616.411.41214.323.41698.376.72815.110.458.65.6010.647.925.655.213.78
0.20.20.20.30.50.40.60.3000.600.10.20.10.40.30.600.822.130.62-0.260.05
0.100.40.50.20.10.10.20.20.20.40.70.20.80.91.41.32.500000.490.72
0.40.40.50.50.40.40.80000000000000.720.780.810.855.04
0.20.20.30.20.20.60.10.200.40.10.50.10.10.20.10.10.300.790.864.540.130.45
4.32.1612.117.712.913.61523.616.699.477.928.416.211.66.910.39012.9711.6911.616.4110.03
1.11.52.11.91.62.41.81.30.91.51.21.20.90.70.40.30.20.503.323.051.451.281.76
00.35.63.57.45.61.92.42.41.80000000000007.142.99
000000000000000000000000
000000000003.430000001.360.76000
000000000000000000000000
00.20.2000000000.10.30.30.10.10.10.104.520.90.220.210.1
1.127.95.4983.73.73.33.31.24.74.210.50.40.30.609.24.71.668.634.85
5.44.113.917.526.720.917.318.726.919.9100.682.632.617.212.17.310.69.6022.1816.3913.2815.0414.88
                                               
17.719.142.553.263.663.667.173.888.488.5189.2191.4152.2152.2152.2152.2158.3158.3036.2136.2136.2136.2136.21
0000000000003.33.33.43.53.53.63.7600000
4.16.3-30-37.3-38.5-44.6-52.2-57-62.9-70.6-91.2-116-124.7-140.6-146.7-150.1-152.2-1540-15.22-21.61-24.94-23.35-30.41
-17,200-22,600000-500-3000000-100010010010010010070.9600000
000000000000000000000000
4.62.812.515.925.118.514.616.825.517.99875.330.81595.79.783.8320.9914.611.2712.865.8
0.51.111.31.3110.70.30.40.80.60.70.30.200.20.401.161.360.740.170.79
0000000000000000200300364.3900000
0.10.10.20.20.20.91.51.11.21.21.66.511.72.81.50.20.900.020.020.660.873.99
000000.400000000000000000.952.77
10001000000000000000000000190.8195.06
0.71.21.31.51.52.32.51.81.51.62.47.11.7231.50.61.60.361.181.381.42.187.74
0.10.100.100000000000000000001.34
000000000000000000000000
000001001001001003003002002002002002002000014.6220.3425.5200
0.10.100.100.10.10.10.10.30.30.20.20.20.20.20.2000.010.020.0301.34
0.81.31.31.61.52.42.61.91.61.92.77.31.92.23.21.70.81.60.361.191.41.432.189.09
5.44.113.817.526.620.917.218.727.119.8100.782.632.717.212.27.410.59.64.1922.181612.715.0414.88
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of TBG Diagnostics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand TBG Diagnostics's financial health and stability.

Assets

TBG Diagnostics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that TBG Diagnostics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of TBG Diagnostics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into TBG Diagnostics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1997199819992000200120022003200420052006200720082009201020112012201320142015null20162017201820192020
0000000000000000000000000
0000000000000000000000000
0000000000000000000000000
0000111111264000000001000
0000000000000000000000000
0000000000000000000000000
0000000000000000000000000
-2-4-7-5-5-4-4-5-5-6-9-15-15-12-4-5-2-2-1-4-2-2-2-2-3
00000-1000-100000000-3-100-100
1-1-6000110-1000-1170-34-212-10000
2-1-51002100000-1170-34114-10100
0000000000000000000000000
0000000000000000000000002
13181111036150990-39000600000000
1317101003614092-1-39000600000002
---1.00--------6.00--------------
0000000000000000000000000
-3-6-40-1-10-5-42-1570-43-68-37-2-10-3-1-38-6-6-4-3-4
0000000000000000000000000
0000000000000000000000000

TBG Diagnostics stock margins

The TBG Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of TBG Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for TBG Diagnostics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the TBG Diagnostics's sales revenue. A higher gross margin percentage indicates that the TBG Diagnostics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the TBG Diagnostics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the TBG Diagnostics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the TBG Diagnostics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the TBG Diagnostics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the TBG Diagnostics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

TBG Diagnostics Margin History

TBG Diagnostics Gross marginTBG Diagnostics Profit marginTBG Diagnostics EBIT marginTBG Diagnostics Profit margin
2025e57.95 %0 %0 %
2024e57.95 %0 %0 %
2023e57.95 %0 %0 %
2022e57.95 %0 %0 %
2021e57.95 %0 %0 %
202057.95 %-65.6 %-76.57 %
201976.11 %-59.51 %22.21 %
201888.83 %-81.65 %-128.17 %
201783.17 %-37.23 %-142.25 %
201670.69 %-201.63 %-188.36 %
201567.81 %-230.55 %-230.55 %
201454.96 %-31.48 %-31.48 %
201357.95 %-80.06 %-59.54 %
20127.61 %-119.03 %-119.03 %
201131.61 %-164.85 %-166.21 %
201025.46 %-420.66 %-584.5 %
200965.99 %-248.79 %-110.73 %
200858.02 %-399.38 %-403.55 %
200737.3 %-546.56 %-593.92 %
200626.24 %-246.81 %-269.86 %
200583.6 %-190.35 %-191 %
200472.21 %-72.05 %-77.22 %
200374.88 %-45.96 %-92.89 %
200261.84 %-85.87 %-108.83 %
200159.15 %-178.03 %-32.39 %

TBG Diagnostics Stock Sales Revenue, EBIT, Earnings per Share

The TBG Diagnostics earnings per share therefore indicates how much revenue TBG Diagnostics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue TBG Diagnostics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates TBG Diagnostics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of TBG Diagnostics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating TBG Diagnostics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

TBG Diagnostics Revenue, EBIT and net profit per share

DateTBG Diagnostics Sales per ShareTBG Diagnostics EBIT per shareTBG Diagnostics Earnings per Share
2025e0.98 undefined0 undefined0 undefined
2024e0.84 undefined0 undefined0 undefined
2023e0.72 undefined0 undefined0 undefined
2022e0.59 undefined0 undefined0 undefined
2021e0.52 undefined0 undefined0 undefined
20200.02 undefined-0.01 undefined-0.02 undefined
20190.02 undefined-0.01 undefined0 undefined
20180.01 undefined-0.01 undefined-0.02 undefined
20170.02 undefined-0.01 undefined-0.03 undefined
20160.01 undefined-0.01 undefined-0.01 undefined
20150 undefined-0.01 undefined-0.01 undefined
20140.1 undefined-0.03 undefined-0.03 undefined
20130.13 undefined-0.1 undefined-0.07 undefined
20120.11 undefined-0.13 undefined-0.13 undefined
20110.13 undefined-0.22 undefined-0.22 undefined
20100.1 undefined-0.42 undefined-0.58 undefined
20090.08 undefined-0.2 undefined-0.09 undefined
20080.1 undefined-0.39 undefined-0.39 undefined
20070.08 undefined-0.42 undefined-0.45 undefined
20060.06 undefined-0.15 undefined-0.17 undefined
20050.08 undefined-0.15 undefined-0.15 undefined
20040.17 undefined-0.12 undefined-0.13 undefined
20030.3 undefined-0.14 undefined-0.28 undefined
20020.19 undefined-0.16 undefined-0.2 undefined
20010.12 undefined-0.22 undefined-0.04 undefined

TBG Diagnostics business model

TBG Diagnostics Ltd is an Australian company specializing in the manufacturing and marketing of in vitro diagnostic products. The company was originally founded in 2009 under the name TBG Biotechnology Pty Ltd and later became a corporation. The company's business model is to provide fast and reliable diagnostic solutions for various disease conditions. The company operates in various areas, including infectious diseases, diarrheal diseases, tumor diagnostics, cardiovascular diseases, and oncology. In the infectious diseases field, for example, TBG Diagnostics offers test kits for the diagnosis of HIV, hepatitis, dengue fever, and other infectious diseases. The test kits consist of immunological rapid tests that typically provide results within 15-20 minutes, allowing doctors to quickly make a diagnosis and initiate appropriate therapy. In the diarrheal diseases field, the company has developed a special test kit that allows for the detection of rotaviruses. Rotavirus infections are one of the most common causes of severe diarrhea in infants and can lead to serious complications if left untreated. TBG Diagnostics' tumor diagnostics division offers specialized test kits for the diagnosis of prostate cancer, breast cancer, and colorectal cancer. The test kits are based on the measurement of tumor markers in the blood and are a fast and non-invasive method for early cancer detection. The company's cardiovascular division offers test kits for the diagnosis of thyroid hormones and troponin. Troponin is a protein complex that is released into the blood in increased amounts when there is damage to the heart muscle and can be an indication of a heart attack. In collaboration with partners, TBG Diagnostics also develops innovative solutions for oncology. One example is a special test kit that enables personalized medicine for patients with advanced bladder cancer. The test kit analyzes the DNA of tumor cells and allows doctors to find individually tailored therapies for the patient. TBG Diagnostics is a successful company that has experienced steady growth in recent years. The company is listed on the Australian stock exchange and has a strong international distribution network, enabling it to distribute its products worldwide. Overall, TBG Diagnostics is a company specializing in the development and manufacturing of innovative diagnostic products. By focusing on various areas and collaborating with partners, the company can quickly respond to changing requirements in healthcare and offer customized solutions to its customers. TBG Diagnostics is one of the most popular companies on Eulerpool.com.

TBG Diagnostics SWOT Analysis

Strengths

1. Established reputation: TBG Diagnostics Ltd has built a strong reputation in the diagnostics industry for providing accurate and reliable testing solutions.

2. Patented technology: The company holds several patents for its innovative diagnostic tools, giving it a competitive edge in the market.

3. Strong financial position: TBG Diagnostics Ltd enjoys a solid financial position, allowing it to invest in research and development, as well as expansion opportunities.

Weaknesses

1. Limited market presence: TBG Diagnostics Ltd primarily operates in a niche market, which restricts its potential customer base.

2. Dependence on key suppliers: The company relies heavily on a few suppliers for crucial raw materials, which poses a risk to its supply chain stability.

3. Lack of diversification: TBG Diagnostics Ltd heavily focuses on a specific range of diagnostic tests, limiting its ability to address broader healthcare needs.

Opportunities

1. Growing demand for diagnostics: With an increasingly aging population and rising prevalence of chronic diseases, the demand for diagnostic services is expected to continue to grow.

2. Expansion into new markets: TBG Diagnostics Ltd can explore opportunities to expand its operations into untapped geographical markets, thereby increasing its customer base.

3. Strategic partnerships: Collaborating with pharmaceutical companies or healthcare providers can lead to new revenue streams and synergistic benefits.

Threats

1. Intense competition: The diagnostics industry is highly competitive, with numerous established players and constant technological advancements. TBG Diagnostics Ltd may face challenges in standing out.

2. Regulatory hurdles: Stringent regulations and compliance requirements in the healthcare sector could pose obstacles to the development and approval of new diagnostic tests.

3. Economic downturn: A global economic downturn could impact healthcare spending and reduce the demand for diagnostic services, affecting TBG Diagnostics Ltd's revenue and profitability.

TBG Diagnostics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

TBG Diagnostics historical P/E ratio, EBIT multiple, and P/S ratio

TBG Diagnostics shares outstanding

The number of shares was TBG Diagnostics in 2023 — This indicates how many shares 217.587 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue TBG Diagnostics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates TBG Diagnostics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of TBG Diagnostics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating TBG Diagnostics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for TBG Diagnostics.

TBG Diagnostics shareholders

%
Name
Stocks
Change
Date
48.67744 % Medigen Biotechnology Corp105,915,93803/30/2021
18.47534 % Eternal Materials Co Ltd40,200,00003/30/2021
0.99139 % Wang (Fu Mei)2,157,12803/30/2021
0.72444 % Wang (Wen Ming)1,576,28903/30/2021
0.72202 % Lu (Yung Fong)1,571,02003/30/2021
0.60783 % Yang (Lee Li Hsueh)1,322,55803/30/2021
0.46005 % Yang (Hsien-Jung)1,001,00003/30/2021
0.45959 % Chembank Pty. Ltd.1,000,00003/30/2021
0.43476 % Yang (Chi Liang)945,98403/30/2021
0.42787 % Cheng (Wei)931,00003/30/2021
1
2

Most common questions regarding TBG Diagnostics

What values and corporate philosophy does TBG Diagnostics represent?

TBG Diagnostics Ltd represents values of innovation, integrity, and excellence in the diagnostics industry. As a leading provider of advanced diagnostic solutions, the company is committed to delivering accurate and reliable results to healthcare professionals and patients. With a focus on research and development, TBG Diagnostics Ltd strives to introduce innovative technologies that improve diagnostic capabilities and patient outcomes. The company's corporate philosophy is centered around customer satisfaction, operational efficiency, and continuous improvement. Through its dedication to quality and cutting-edge solutions, TBG Diagnostics Ltd aims to contribute to the advancement of healthcare globally.

In which countries and regions is TBG Diagnostics primarily present?

TBG Diagnostics Ltd is primarily present in the Asia-Pacific region. This includes countries such as China, Japan, South Korea, Australia, and Singapore.

What significant milestones has the company TBG Diagnostics achieved?

TBG Diagnostics Ltd has achieved several significant milestones in its company history. Notably, the company successfully developed and launched innovative diagnostic products that have made a profound impact on the healthcare industry. In addition, TBG Diagnostics Ltd expanded its global presence by establishing strategic partnerships with renowned medical institutions and securing regulatory approvals for its products in key markets. Through continuous research and development efforts, the company has consistently delivered advanced diagnostic solutions, ensuring accurate and reliable results for healthcare professionals and patients worldwide. TBG Diagnostics Ltd's commitment to innovation and quality has positioned it as a leading player in the diagnostic industry.

What is the history and background of the company TBG Diagnostics?

TBG Diagnostics Ltd. is a renowned company specializing in medical diagnostic products and systems. Founded in [insert year], the company has a rich history of innovation and steadfast commitment to advancing healthcare services. TBG Diagnostics Ltd. has gained significant recognition for its cutting-edge technologies and diagnostic solutions, catering to the evolving needs of healthcare professionals worldwide. With a strong focus on research and development, the company continuously strives to introduce pioneering products that revolutionize the field of diagnostics. TBG Diagnostics Ltd. has established itself as a trusted name in the industry, delivering accurate results and contributing to better patient outcomes.

Who are the main competitors of TBG Diagnostics in the market?

The main competitors of TBG Diagnostics Ltd in the market are Bio-Rad Laboratories, Inc., Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific Inc., and Abbott Laboratories. These companies are also prominent players in the healthcare and diagnostics industry, offering a range of products and services similar to TBG Diagnostics Ltd. These competitors pose a significant challenge to TBG Diagnostics Ltd in terms of market share and innovation.

In which industries is TBG Diagnostics primarily active?

TBG Diagnostics Ltd primarily operates in the healthcare and medical diagnostics industry.

What is the business model of TBG Diagnostics?

TBG Diagnostics Ltd is a company engaged in the business of providing diagnostic solutions and services. They specialize in developing and manufacturing in-vitro diagnostic products for the detection, monitoring, and management of a wide range of diseases and medical conditions. Their business model revolves around the research, development, and commercialization of innovative diagnostic technologies and products. By leveraging their expertise in molecular diagnostics, immunodiagnostics, and clinical chemistry, TBG Diagnostics aims to contribute to the improvement of global healthcare outcomes. With their focus on delivering high-quality and accurate diagnostic solutions, TBG Diagnostics Ltd positions itself as a reliable and trusted partner in the healthcare industry.

What is the P/E ratio of TBG Diagnostics 2024?

The TBG Diagnostics P/E ratio is 0.

What is the P/S ratio of TBG Diagnostics 2024?

The TBG Diagnostics P/S ratio is 0.32.

What is the AlleAktien quality score of TBG Diagnostics?

The AlleAktien quality score for TBG Diagnostics is 5/10.

What is the revenue of TBG Diagnostics 2024?

The expected TBG Diagnostics revenue is 182.76 M AUD.

How high is the profit of TBG Diagnostics 2024?

The profit cannot currently be calculated for TBG Diagnostics.

What is the business model of TBG Diagnostics

TBG Diagnostics Ltd is a company specialized in the development, manufacturing, and marketing of medical diagnostic products and services. The company is divided into different business divisions that offer various products and services. The first business division of TBG Diagnostics Ltd is the production of clinical diagnostics. In this division, the company manufactures different products such as antibodies, enzymes, and antigens used in medical diagnostics. These products are sold to other companies that incorporate them into their own products. The second business division of TBG Diagnostics Ltd is the development and manufacturing of in vitro diagnostics (IVD). These products are used for diagnosing and monitoring diseases and conditions in patients. IVD products manufactured by TBG Diagnostics Ltd include blood glucose meters, urea test strips, pregnancy tests, and tests for infectious diseases such as HIV. Another business division of TBG Diagnostics Ltd is clinical trials. The company provides services in the field of clinical research and development of medical devices. It conducts clinical studies to test the effectiveness and safety of medical devices developed by other companies. TBG Diagnostics Ltd works closely with other companies to find medical solutions that ultimately benefit patients. In addition to these business divisions, TBG Diagnostics Ltd also offers other services. For example, the company provides consulting services to support customers in product development and marketing. It also offers training for customers to educate them on the use of TBG Diagnostics Ltd products and services and keep them informed about the latest developments in the medical sector. TBG Diagnostics Ltd's business model is based on the development and marketing of innovative medical diagnostic products and services. The company collaborates closely with other companies to develop medical products and services that improve patients' health. It is a leading provider of IVD products and clinical diagnostics sold worldwide. In a market characterized by rapid changes and technological innovation, TBG Diagnostics Ltd continually invests in research and development to ensure it keeps pace with the latest trends and developments in the medical sector. As a company specialized in the development of medical products and services for the healthcare sector, TBG Diagnostics Ltd is well-positioned to continue growing and succeeding in the future.

What is the TBG Diagnostics dividend?

TBG Diagnostics pays a dividend of 0 AUD distributed over payouts per year.

How often does TBG Diagnostics pay dividends?

The dividend cannot currently be calculated for TBG Diagnostics or the company does not pay out a dividend.

What is the TBG Diagnostics ISIN?

The ISIN of TBG Diagnostics is AU000000TDL4.

What is the TBG Diagnostics WKN?

The WKN of TBG Diagnostics is A2AD8F.

What is the TBG Diagnostics ticker?

The ticker of TBG Diagnostics is TDL.AX.

How much dividend does TBG Diagnostics pay?

Over the past 12 months, TBG Diagnostics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TBG Diagnostics is expected to pay a dividend of 0 AUD.

What is the dividend yield of TBG Diagnostics?

The current dividend yield of TBG Diagnostics is .

When does TBG Diagnostics pay dividends?

TBG Diagnostics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of TBG Diagnostics?

TBG Diagnostics paid dividends every year for the past 0 years.

What is the dividend of TBG Diagnostics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is TBG Diagnostics located?

TBG Diagnostics is assigned to the 'Health' sector.

Wann musste ich die Aktien von TBG Diagnostics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of TBG Diagnostics from 10/4/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did TBG Diagnostics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of TBG Diagnostics in the year 2023?

In the year 2023, TBG Diagnostics distributed 0 AUD as dividends.

In which currency does TBG Diagnostics pay out the dividend?

The dividends of TBG Diagnostics are distributed in AUD.

All fundamentals about TBG Diagnostics

Our stock analysis for TBG Diagnostics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TBG Diagnostics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.